In metastatic tumors, MEK inhibitors (selumetinib, trametinib) have shown great benefit in NF1 patients because they inhibit the MAP kinase pathway, which is overactivated due to NF1 mutation. The gene discussed is MAP2K7; the disease is metastatic neoplasm.